Login to Your Account

Cabo Developer Continues to Trim Pipeline

Exelixis, Sanofi Terminate Preclinical PI3K Programs

By Marie Powers
Staff Writer

Tuesday, December 27, 2011
A day after inking a potential $251 million agreement with Merck & Co. Inc. to license out its phosphoinositide-3 kinase (PI3K)-delta research and development program, Exelixis Inc. trimmed its pipeline further, agreeing to terminate the preclinical programs that were part of a blockbuster 2009 PI3K collaboration with Sanofi-Aventis SA, of Paris.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription